

Title (en)  
RIBOZYME THERAPY FOR RESTENOSIS

Title (de)  
RIBOZYMOTHERAPIE FÜR RESTENOSE

Title (fr)  
THERAPIE A BASE DE RIBOZYMES POUR TRAITER LA RESTENOSE

Publication  
**EP 0750503 A4 19990721 (EN)**

Application  
**EP 95913613 A 19950306**

Priority  
• US 9502926 W 19950306  
• US 20764994 A 19940307

Abstract (en)  
[origin: WO9524202A1] As an effective therapy for restenosis, this invention provides ribozymes and ribozyme delivery systems useful to inhibit abnormal smooth muscle cell proliferation in vascular tissue. Methods of producing ribozymes and gene therapy utilizing these ribozymes also are provided.

IPC 1-7  
**A61K 31/70**; **C12N 5/16**; **C12N 9/22**; **C12N 15/85**; **C12N 15/86**; **C12Q 1/25**

IPC 8 full level  
**C12N 15/09** (2006.01); **A61K 31/70** (2006.01); **A61K 35/12** (2006.01); **A61K 35/76** (2006.01); **A61K 48/00** (2006.01); **A61P 9/00** (2006.01); **C07H 21/04** (2006.01); **C12N 5/10** (2006.01); **C12N 9/00** (2006.01); **C12N 15/113** (2010.01); **A61K 38/00** (2006.01)

CPC (source: EP)  
**A61P 9/00** (2017.12); **C12N 15/113** (2013.01); **C12N 15/1135** (2013.01); **C12N 15/1136** (2013.01); **C12N 15/1137** (2013.01); **C12Y 104/03013** (2013.01); **C12Y 207/11022** (2013.01); **A61K 38/00** (2013.01); **A61K 48/00** (2013.01); **C12N 2310/111** (2013.01); **C12N 2310/121** (2013.01); **C12N 2310/122** (2013.01); **C12N 2310/3531** (2013.01); **C12N 2799/022** (2013.01); **C12N 2799/025** (2013.01)

Citation (search report)  
• [XY] WO 9119789 A1 19911226 - COMMW SCIENT IND RES ORG [AU]  
• [Y] WO 9308845 A1 19930513 - MASSACHUSETTS INST TECHNOLOGY [US]  
• [E] WO 9531541 A2 19951123 - RIBOZYME PHARM INC [US]  
• [Y] DZAU, V. ET AL.: "Antisense technology to block autocrine growth factors", JOURNAL OF VASCULAR SURGERY, vol. 15, May 1992 (1992-05-01), pages 934 - 935, XP002091739  
• [DY] CHATTERJEE, S. ET AL.: "Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector.", SCIENCE., vol. 258, 27 November 1992 (1992-11-27), pages 1485 - 1488, XP002091740  
• [A] NABEL, E. ET AL.: "Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivo", J. CLIN. INVEST., vol. 91, April 1993 (1993-04-01), pages 1822 - 1829, XP002091741  
• [A] RAINES E W ET AL: "INTERLEUKIN-1 MITOGENIC ACTIVITY FOR FIBROBLASTS AND SMOOTH MUSCLE CELLS IS DUE TO PDGF-AA", SCIENCE, vol. 243, 20 January 1989 (1989-01-20), pages 393 - 396, XP002035384  
• [PX] STINCHCOMB D T ET AL: "TOWARDS THE APPLICATION OF RIBOZYMES TO HUMAN HEALTH", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 19A, 1995, pages 202, XP002024062  
• See references of WO 9524202A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB GR IE IT LI MC NL PT SE

DOCDB simple family (publication)  
**WO 9524202 A1 19950914**; AU 2099095 A 19950925; CA 2184989 A1 19950914; EP 0750503 A1 19970102; EP 0750503 A4 19990721; JP H09510101 A 19971014

DOCDB simple family (application)  
**US 9502926 W 19950306**; AU 2099095 A 19950306; CA 2184989 A 19950306; EP 95913613 A 19950306; JP 52363495 A 19950306